reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration

Leuven Belgium, 31 August 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces positive preclinical results from its drug discovery program ReS18-H to treat Huntington’s Disease (HD), a rare monogenic disease that causes the progressive breakdown of nerve cells in the brain by neurotoxic mutant huntingtin, leading to movement, cognitive and psychiatric dysfunction.

Read more
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a

Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces that its lead Alzheimer program ReS19-T has successfully completed its Phase 1 study. Topline data has demonstrated excellent brain exposure and strong safety profile. These results support the next phase of clinical development, a Phase 2a proof-of-mechanism study slated for initiation soon.

Read more
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program

Leuven Belgium, 4 November 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes, epilepsy and other diseases caused by cellular dysfunction, today announces the acceptance of ReS3-T, the Company’s lead epilepsy drug candidate, into the US NIH’s National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). The ReS3-T program is the result of a collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3).

Read more
reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

Leuven Belgium, 21 October 2021: reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Read more
reMYND announces Clinical Advisory Board to support development of Alzheimer’s programme

Leuven Belgium, 20 May 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, is pleased to announce the Clinical Advisory Board (CAB) which will support the Company as it progresses its programme in Alzheimer’s disease (“Alzheimer’s”).

Read more
reMYND appoints Dr. Lode Debrabandere as Chief Business Officer
Read more
reMYND commences first-in-human trial of ReS19-T Alzheimer’s program

-  RES-19T represents a novel approach to treat Alzheimer’s at the root of the disease and restore cognition

-  Board and Senior Leadership team strengthened; appointment of Staph Leavenworth Bakali as Chair and Hermann Russ as Chief Medical Officer


Read more
Interreg. project "Memories" update

An intermediate update on the progress of identifying differently expressed microRNA in Alzheimer's Disease.

Read more
Interreg. project "Memories" holds 2nd annual symposium & new newsletter is available

The Interreg. Flanders-Netherlands project "Memories" (Dutch: "Herinneringen") will hold its 2nd annual Symposium on December 16th, 2019 in Leuven. The initial gathered data on activated mechanisms after addition of Alzheimer-related mechanisms will be presented. The intermediary update is available in the third newslette. Visit to receive the latest updates.

Read more
reMYND raises 12 million EUR to assess clinical proof-of-mechanism in Alzheimer’s and to expand into orphan disorders

Leuven Belgium, December 18th, 2018: reMYND NV announced today the closing of a 12 million EUR financing round to

  • advance its Alzheimer program into clinical testing and assess its novel mechanism in patients;
  • broaden the pipeline into CNS orphan programs, including Huntington and ALS;
  • further innovate and expand the service offering of its CRO;
  • and strengthen the executive team and board.
Read more